

John K Hsiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8842817/publications.pdf>

Version: 2024-02-01

58
papers

14,517
citations

87888

38
h-index

138484

58
g-index

59
all docs

59
docs citations

59
times ranked

9076
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1209-1223. | 27.0 | 5,335 |
| 2 | Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 1525-1538. | 27.0 | 1,067 |
| 3 | Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005, 80, 19-32. | 2.0 | 1,016 |
| 4 | Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633. | 12.3 | 928 |
| 5 | Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610. | 7.2 | 760 |
| 6 | Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600. | 7.2 | 513 |
| 7 | Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417. | 7.2 | 390 |
| 8 | Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-622. | 7.2 | 312 |
| 9 | Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. <i>American Journal of Psychiatry</i> , 2008, 165, 844-854. | 7.2 | 274 |
| 10 | Diagnosing Diagnoses. <i>Archives of General Psychiatry</i> , 1989, 46, 664. | 12.3 | 263 |
| 11 | Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i>Schizophrenia Research</i> , 2008, 101, 273-286. | 2.0 | 258 |
| 12 | Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080-2089. | 7.2 | 247 |
| 13 | Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428-436. | 7.2 | 246 |
| 14 | Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. <i>American Journal of Psychiatry</i> , 2011, 168, 831-839. | 7.2 | 232 |
| 15 | Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611. | 7.2 | 221 |
| 16 | Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008, 105, 175-187. | 2.0 | 195 |
| 17 | The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls. <i>Neuropsychopharmacology</i> , 1993, 9, 277-291. | 5.4 | 166 |
| 18 | National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 346-360. | 1.2 | 156 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Quantitative Examination of Tissue Concentration Profiles Associated with Microdialysis. <i>Journal of Neurochemistry</i> , 1992, 58, 931-940. | 3.9 | 141 |
| 20 | Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427. | 7.2 | 138 |
| 21 | Quantitative Microdialysis: Analysis of Transients and Application to Pharmacokinetics in Brain. <i>Journal of Neurochemistry</i> , 1991, 57, 103-119. | 3.9 | 135 |
| 22 | Effects of Different Semipermeable Membranes on In Vitro and In Vivo Performance of Microdialysis Probes. <i>Journal of Neurochemistry</i> , 1990, 54, 1449-1452. | 3.9 | 133 |
| 23 | Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009, 107, 1-12. | 2.0 | 129 |
| 24 | Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506. | 2.0 | 110 |
| 25 | Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Biological Psychiatry</i> , 2009, 66, 1013-1022. | 1.3 | 91 |
| 26 | Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. <i>American Journal of Psychiatry</i> , 2009, 166, 583-590. | 7.2 | 76 |
| 27 | Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 529-536. | 2.8 | 74 |
| 28 | In Vivo Evidence that Lithium Inactivates GiModulation of Adenylate Cyclase in Brain. <i>Journal of Neurochemistry</i> , 1992, 59, 200-205. | 3.9 | 73 |
| 29 | Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459. | 4.3 | 65 |
| 30 | Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008, 103, 104-109. | 2.0 | 64 |
| 31 | The Effects of Intravenous Clomipramine on Neurohormones in Normal Subjects*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 68, 632-637. | 3.6 | 62 |
| 32 | Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2007, 64, 1259. | 12.3 | 57 |
| 33 | Monoamine Neurotransmitter Interactions and the Prediction of Antidepressant Response. <i>Archives of General Psychiatry</i> , 1987, 44, 1078. | 12.3 | 54 |
| 34 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. <i>Schizophrenia Research</i> , 2008, 100, 39-52. | 2.0 | 53 |
| 35 | Abnormal neuroendocrine responsivity to acute I.V. clomipramine challenge in depressed patients. <i>Psychiatry Research</i> , 1990, 31, 39-47. | 3.3 | 48 |
| 36 | Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. <i>Brain Research</i> , 1991, 538, 333-336. | 2.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 547-554. | 4.7 | 40 |
| 38 | Lithium administration modulates platelet Gi in humans. <i>Life Sciences</i> , 1992, 50, 227-233. | 4.3 | 39 |
| 39 | Quantitative microdialysis. <i>Handbook of Behavioral Neuroscience</i> , 1991, 7, 47-80. | 0.0 | 35 |
| 40 | Intravenous alprazolam challenge in normal subjects. <i>Psychopharmacology</i> , 1989, 99, 508-514. | 3.1 | 32 |
| 41 | A study of the TRH test in a family with psychiatric illness: A reflection on the TRH test as a state-trait marker. <i>Biological Psychiatry</i> , 1985, 20, 570-572. | 1.3 | 29 |
| 42 | In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. <i>Experimental Neurology</i> , 1990, 110, 187-193. | 4.1 | 27 |
| 43 | Clinical investigation of monoamine neurotransmitter interactions. <i>Psychopharmacology</i> , 1993, 112, S76-S84. | 3.1 | 27 |
| 44 | Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 103-111. | 1.4 | 24 |
| 45 | Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. <i>Experimental Neurology</i> , 1990, 110, 181-186. | 4.1 | 23 |
| 46 | Interpreting the Results of the CATIE Study. <i>Psychiatric Services</i> , 2006, 57, 139-139. | 2.0 | 18 |
| 47 | Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Journal of Psychiatry)</i> , 2014, 14, 107-114. | 1.4 | 17 |
| 48 | Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression?. <i>Biological Psychiatry</i> , 1986, 21, 595-600. | 1.3 | 16 |
| 49 | ECT and Neurological Disorders. <i>Convulsive Therapy</i> , 1987, 3, 121-136. | 0.1 | 15 |
| 50 | Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 797-808. | 2.4 | 12 |
| 51 | A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 12063. | 3.3 | 11 |
| 52 | Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. <i>Psychopharmacology</i> , 1993, 111, 295-300. | 3.1 | 9 |
| 53 | Dr. Rosenheck and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 678-680. | 7.2 | 7 |
| 54 | REGIONAL BRAIN METABOLISM AS PREDICTORS OF CLOZAPINE RESPONSE. <i>Clinical Neuropharmacology</i> , 1992, 15, 399A-400A. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Medication-free Intervals and Schizophrenia Research--Editors' Introduction. Schizophrenia Bulletin, 1997, 23, 1-1. | 4.3 | 3 |
| 56 | Cardiovascular response to speaking in schizophrenics. Psychiatry Research, 1987, 22, 69-79. | 3.3 | 2 |
| 57 | Activation in young rats induced by LY134046, an inhibitor of phenylethanolamine N-methyltransferase. Psychopharmacology, 1989, 98, 240-244. | 3.1 | 2 |
| 58 | ECT treatment does not enhance neuroendocrine responses to serotonergic challenge. Journal of Psychopharmacology, 1992, 6, 501-508. | 4.0 | 2 |